Verona Pharma plc — Director's Dealing 2022

Sep 28, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Verona Pharma plc (VRNA)
CIK: 0001657312
Period of Report: 2022-09-26

Reporting Person: ZACCARDELLI DAVID (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-09-26	Ordinary Shares	A	3600000	—	Acquired	18863560	Direct

Footnotes

F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F2: Represents an award of Restricted Share Units ("RSUs"), each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer. The RSUs vest over four years, with 900,000 RSUs vesting on November 1, 2023 and the balance vesting in 12 equal quarterly installments thereafter.

F3: Consists of (i) 10,702,720 Ordinary Shares underlying RSUs (which are represented by 1,337,840 ADSs); and (ii) 8,160,840 Ordinary Shares underlying 1,020,105 ADSs.